Navigation Links
Advanced Health Media Company Announces Renee DeFranco as Senior Vice President - Human Resources
Date:1/27/2011

olutions and sales support services designed to address the diverse operational and compliance management needs of its clients, including corporate speaker bureau and event management solutions, sales force automation technology, customer relationship management, and compliance tracking and reporting systems. AHM also provides full-service medical communications, including strategic communication strategy, publication planning, scientific meetings and key opinion leader advocacy development. AHM provides services to more than 50 companies in the pharmaceutical sector.

Headquartered in Bridgewater, NJ, with offices in Union and Somerville, NJ, Chesapeake, VA and Chicago, IL, AHM is the parent company of AHM Solutions, Centeon Solutions, Embryon, LLC, Ephikacy, LLC, Cogenix, LLC, ProMedix, LLC, and InsiteResearch, LLC. For more information, please visit the AHM Web site at www.ahmdirect.com.


'/>"/>
SOURCE Advanced Health Media LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. New materials may bring advanced optical technologies, cloaking
2. Advanced Pain Remedies, a Subsidiary of Cato BioVentures, Announces a Three Million Dollar Award from the National Cancer Institute for SP-SAP
3. Advanced BioHealing to Present at 29th Annual J.P. Morgan Healthcare Conference
4. Advanced Life Sciences to Present at the Biotech Showcase™ 2011 Conference
5. Vaccinex, Inc. Initiates Clinical Trial of Novel Therapeutic Antibody in Cancer Patients With Advanced Solid Tumors
6. Zeus Expands Class 7 Capabilities to Include the Processing of Advanced Polymers
7. Teysuno™ (S-1) Receives CHMP Positive Opinion for Approval as First-Line Therapy for Advanced Gastric Cancer
8. Wiley-VCH launches new journal Advanced Energy Materials
9. Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany
10. Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo
11. StemCyte Awarded $488,950 for Advanced Therapeutic Applications of Umbilical Cord Blood Stem Cells from the Qualifying Therapeutic Discovery Project (QTDP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... ... cognition grew 31% in 2009, to $295M worldwide; and is forecasted to reach $4B in ... San Francisco, CA ... technologies to assess, enhance and treat cognition, or digital brain health and fitness ...
... , June 27, 2010 , , ... - Outstanding Young Women Biologists, Chemists, Physicists and,Mathematicians Recognized Across the Developing World , ... The Elsevier Foundation, TWAS and TWOWS announced ... East , Asia , Latin America and the Caribbean for their ...
... ORLANDO, Fla. , June 26, 2010 ... announced results from an analysis of an integrated database ... cardiovascular (CV) events associated with SYMLIN® (pramlintide acetate) injection ... either placebo or rapid-acting insulin. These findings were presented ...
Cached Biology Technology:New Report Finds A Brain Health Revolution in the Making, Driven by Digital Technology and Neuroplasticity Research 2New Report Finds A Brain Health Revolution in the Making, Driven by Digital Technology and Neuroplasticity Research 3New Report Finds A Brain Health Revolution in the Making, Driven by Digital Technology and Neuroplasticity Research 4New Report Finds A Brain Health Revolution in the Making, Driven by Digital Technology and Neuroplasticity Research 5Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 2Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 3Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 4Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 5Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 6Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 7Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 2Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 3Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 4Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 5Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 6Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 7
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the ... the post-password and Internet of Things era, today announced ... The venture round was led by Metamorphic Ventures with ... Venture Partners, VegasTechFund, and others.  LaunchKey has raised $4 ... to expand its team and bring LaunchKey to market ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and Markets ... addition of the "Global Chemical Sensor Market ... http://photos.prnewswire.com/prnh/20130307/600769 One ... increasing demand for medical sensors in biomedical applications. ... for quick and correct diagnosis during surgical procedures. ...
(Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays ... a while. Hypertension – the medical term for high blood ... early 1800s, and the inflatable cuff that,s used in measuring ... however, mean there,s nothing new about hypertension, its triggers and ... beliefs about the condition and the best ways to treat ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... The International Cooperation to Sequence the Atlantic ... Phase II contract for next-generation sequencing and analysis ... Craig Venter Institute (JCVI) in Rockville, Maryland. The ... next-generation technologies, including assembly to integrate Sanger and ...
... latest invader of the Great Lakes Hemimysis anomala , or ... spotsmay become a new food source for fish, allaying concerns ... "Forecasting how an invader will affect the growth and ... to conservation groups and government agencies hoping to conserve those ...
... month in the Journal of the American Chemical Society ... at San Antonio have pinpointed the cancer-fighting potential in the ... Ph.D., leader of the Experimental Development Therapeutics Program at the ... at the UT Health Science Center, has been working to ...
Cached Biology News:Salmon genome in final phases of completion 2Bat plant could give some cancers a devil of a time 2
... Simplify the process and you reduce the ... into the CEQ 8000. Developed using Beckman ... leadership in capillary electrophoresis technology, the CEQ ... system. This system automatically fills the capillary ...
... standard electrophoresis hood is a ... systems. Placed on the transilluminator, ... place and provides a darkroom ... the lab bench. This 13 ...
... Zyagen tissue microarrays are derived from ... to rigorous quality control procedures to ensure ... are manually assembled in one block, sectioned ... mounted on coated slides. Sections are large ...
... Zyagen tissue microarrays are derived from Paraffin ... rigorous quality control procedures to ensure the ... manually assembled in one block, sectioned at ... on coated slides. Sections are large (3-5 ...
Biology Products: